Preclinical triple-humanized PD-1/GITR/GITRL mouse model

The hPD-1/hGITR/hGITRL mouse model enables in vivo efficacy assessment and profiling of antibodies targeting human immune checkpoint PD-1, GITR and/or GITRL in fully immunocompetent mice.

Applications & Features
Resources
Validation Data

Design of the hPD-1/hGITR/hGITRL mouse

The triple-humanized PD‑1, GITR and GITRL mouse model (hPD-1/hGITR/hGITRL) was generated by intercrossing hPD-1, hGITR and hGITRL mice.‍

hPD-1 was generated by inserting, within the mouse Pd-1 locus, a chimeric PD-1 with the human extracellular and murine transmembrane and intracellular domains.

hGITR was developed by inserting, within the mouse Gitr locus, a chimeric GITR with the human extracellular and the murine intracellular domain.

hGITRL was generated by inserting, within the mouse Gitrl locus, a chimeric GITRL with the human extracellular and the murine intracellular domain.

hPD-1, hGITR and hGITRL expressions are regulated by endogenous mouse promoters.

‍

hPD-1/hGITR/hGITRL features

PD-1, GITR and GITRL extracellular domains are entirely humanized
hPD-1, hGITR and hGITRL expression driven by the respective endogenous mouse promoter
Fully functional mouse immune system
Lack of expression of the murine target genes, thus avoiding cross-reactivity

Clients

No items found.

Related resources and publications

osteomyelitis

hyperalgesia

PET imaging

intrauterine growth deficiency

Myopia

ossification

cGAS

cGAS-STING pathway

TFRC

FX-deficiency

muscle-eye-brain disease (MEB)

Tumor microenvironment

primary immunodeficiency (PID)

Oncology

Pharmacology

Neuroscience

Metabolism

Inflammation

Immunology

Respiration

Cardiovascular

Ophthalmology

Nephrology

Musculoskeletal

Hematology

Epigenetics

Development

Endocrinology

Dermatology

Humanization

Rosa26

TET system

Hprt

CreERt2

FLEx

innate immunity

Transgenesis

infection

vision

immune response

dementia

central nervous system (CNS)

taste

transplantation

autoimmunity

thermoregulation

sugar homeostasis

stress

skelet

pulmonary research

pain research

nutrition

muscle research

locomotion

memory

hearing

fat homeostatsis

tissue research

epigentic modification

drugs

cancer research

cell research

behavior

aging

stem cell research

reproductive research

lymphatic system

learning

heart research

gut research

genetic research

exercise

bone research

embryonic development

dental research

blood research

von Willebrand disease (VWD)

X-linked adrenoleukodystrophy (X-ADL)

Vanishing White Matter (VWM) disease

type 2 diabetes (T2D)

ulcerative colitis (UC)

type 1 diabetes (T1D)

thrombosis

thrombocytopenia

systemic lupus erythematosus (SLE)

tauopathy

stenosis

steatohepatitis

spinocerebellar ataxia type 2 (SCA2)

small cell lung cancer

SHORT syndrome

sepsis

schizophrenia

Senescence-associated secretory phenotype (SASP)

seizure

sarcoidosis

rhesus-deficiency syndrome

retinopathy

retinitis pigmentosa (RP)

retinal dystrophy disorder

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

(Cidara) Discovery of a multispecific CD73/PD-1 targeting Drug Fc-Conjugate (DFC), which improves tumor reduction compared to PD-1 monotherapy in a humanized mouse model

Multispecific CD73/PD-1 targeting

Apr 2024

(Bonum) A Novel Method for Generating Regulated Cytokine Therapeutics: Safety and Activity of a Conditionally Active cLAG3-IL2 Capable of Delivering IL-2 to LAG-3+ Cells While Remaining Inert on LAG-3- Cells

Safety and activity of a conditionally active cLAG3-IL2

Apr 2024

(Anaveon) ANV600 is a novel PD-1 targeted IL-2Rβ/γ agonist that is combinable with therapeutic PD-1 inhibitors

Novel PD-1 targeted IL-2Rβ/γ agonist

Nov 2023

(Anaveon) ANV600 is a potent, cis-signaling, IL-2Rβ/γ directed IL-2 which efficiently expands intratumoral stem-like CD8 T cells

PD-1 & strong tumor growth inhibition

Apr 2023

(Reaction Biology) Humanized PD-1 knock-in mice as a model system for combination therapies with human specific PD-1 therapeutics

hPD-1 to evaluate novel cancer therapies

Apr 2023

(Charles River) Novel in vivo preclinical humanized models for the evaluation of human specific immune checkpoint inhibitors.

hPD-1/hCTLA-4 mice to evaluate immune checkpoint inhibitors

Nov 2019

(Charles River) Validation of humanized PD-1 knock-in mice as an emerging model to evaluate human specific PD-1 therapeutics

hPD-1 mice as a model to evaluate human specific PD-1 therapeutics

Mar 2019

Human PD-1 agonist treatment alleviates neutrophilic asthma by reprogramming T cells

J Allergy Clin Immunol

Jul 2022

Therapeutic targeting of PD-1/PD-L1 blockade by novel small-molecule inhibitors recruits cytotoxic T cells into solid tumor microenvironment

J Immunother Cancer

Jul 2022

An anti-PD-1–GITR-L bispecific agonist induces GITR clustering-mediated T cell activation for cancer immunotherapy

Nat Cancer

Mar 2022

Highlighted article

read the comment

Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1 + Activated T Cells

Cancer Discov

Dec 2020

VISTA checkpoint inhibition by pH-selective antibody SNS-101 with optimized safety and pharmacokinetic profiles enhances PD-1 response

VISTA - safety and PK profiling

8 min read

Apr 2024

CCX559 is a potent, orally-administered small molecule PD-L1 inhibitor that induces anti-tumor immunity

Humanized ICP mouse and cell lines

9 min read

Jun 2023

A new promising family of small molecules regulating the PD-L1/PD-1 signaling pathway

Humanized PD-1/PD-L1 mouse and cell line

10 min read

Jul 2022

An alternative approach to immunotherapy: A bispecific agonist

Humanized PD-1 & GITR mouse

4 min read

Mar 2022

Uncoupling efficacy from toxicity: a case study on MEDI5752

Bispecific antibodies

5 min read

Apr 2021

No results

Validation data

hPD-1 is expressed on T cells
Freshly isolated splenocytes from wild-type or PD-1/GITR/GITRL triple-humanized mice. mPD-1 and hPD-1 expression were analyzed on single live CD3⁺, CD4⁺CD25^-cells (conv CD4) and CD4⁺CD25⁺Foxp3⁺ cells (Treg). T cells from lymphocytes incubated in the presence of anti-CD3, anti-CD28 and recombinant murine IL-2.
hGITR is expressed on T cells
Freshly isolated splenocytes from wild-type or PD-1/GITR/GITRL triple humanized mice. mGITR and hGITR expression were analyzed on single live CD3⁺, CD4⁺CD25^-cells (conv CD4) and CD4⁺CD25⁺Foxp3⁺ cells (Treg). Cells from lymphocytes were incubated in the presence of anti-CD3, anti-CD28 and recombinant murine IL-2.
In vivo anti-tumor activity is observed in response to anti-PD-1 treatment in hPD-1 mice
Survival of mice of indicated genotype implanted intracranially with GL261 murine glioma cells and treated with αhPD-1 (pembrolizumab), αmPD-1 or isotype (Mantel-Cox test: ***p<0.001).
hGITR-Fc significantly inhibits ear swelling at 24 and 48 hours post DNFB challenge in hGITR/hGITRL mice
Mice were injected with vehicle, IgG, GITR-Fc or mCTLA4-Ig on day -1, sensitized with DNFB on day 0, and then challenged on the ear on day 5. The mean ear-swelling response was determined at 24 and 48 hours post DNFB challenge.

Lag3

ICP (multi-target)

hCTLA-4/hLAG3

The hCTLA-4/hLAG3 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CTLA-4 and/or LAG3 in fully immunocompetent mice.

Immune checkpoint

GITR

ICP (single-target)

hGITR

The hGITR mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint GITR in fully immunocompetent mice.

Immune checkpoint

GITR

GITRL

ICP (multi-target)

hGITR/hGITRL

The hGITR/hGITRL mouse model enables in vivo efficacy assessment and profiling of agonist and antagonist antibodies targeting human immune checkpoint GITR and/or GITRL in fully immunocompetent mice.

Immune checkpoint

OX40

ICP (single-target)

The hPD-1/hVISTA mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint PD-1 and/or VISTA in fully immunocompetent mice.

Immune checkpoint

VISTA

ICP (single-target)

hVISTA

The hVISTA mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint VISTA in fully immunocompetent mice.

PD-L1

Immune checkpoint

MC38

PD-1

MC38-hPD-L1-LZ

The MC38-hPD-L1-LZ clonal cell line expresses high levels of human PD-L1 and forms solid tumors in vivo. An optimized version of a luciferase-ZsGreen (LZ) fusion protein is also stably expressed for in vivo imaging and ex vivo tracking.

Preclinical triple-humanized PD-1/GITR/GITRL mouse model

Get in touch about

Let us know how we can help

First name*

Last name*

Email*

Phone

Company*

Country*

Job title

Message*

In order to provide you the content requested, we need to store and process your personal data. If you consent to us storing your personal data for this purpose, please tick the checkbox below.

I agree to allow genOway to store and process my personal data.*

From time to time, we would like to contact you about our products and services, as well as other content that may be of interest to you. If you consent to us contacting you for this purpose, please tick below.

I agree to receive other communications from genOway.

You can unsubscribe from these communications at any time. For more information on how to unsubscribe, our privacy practices, and how we are committed to protecting and respecting your privacy, please review our Privacy Policy.

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

New humanized

FcγR mouse

Needs

Science

Company

Preclinical triple-humanized PD-1/GITR/GITRL mouse model

Design of the hPD-1/hGITR/hGITRL mouse

hPD-1/hGITR/hGITRL features

Clients

Related resources and publications

Validation data

hPD-1 is expressed on T cells

hGITR is expressed on T cells

In vivo anti-tumor activity is observed in response to anti-PD-1 treatment in hPD-1 mice

hGITR-Fc significantly inhibits ear swelling at 24 and 48 hours post DNFB challenge in hGITR/hGITRL mice

Discover related products to

hPD-1/hGITR/hGITRL

hCD28

hCD39

hCTLA-4

hCTLA-4/hLAG3

hGITR

hGITR/hGITRL

hOX40

hPD-1

hPD-1/hCTLA-4

hPD-1/hLAG3

hPD-1/hPD-L1

hPD-1/hTIM3

hPD-1/hVISTA

hVISTA

MC38-hPD-L1-LZ

Preclinical triple-humanized PD-1/GITR/GITRL mouse model

Get in touch about

Scientific excellence

Robust validation data on catalog models

Customer care

Easy and fast access to models